Therefore, our results suggest that USP22 expression levels alone or combined with HLA-I expression levels and CD8+ T cell infiltration frequency prior to ICB, could serve as a more accurate biomarker to predict the ICB immunotherapeutic response for lung cancer treatment. This evidence concerns the gene USP22 and lung carcinoma.